Results 51 to 60 of about 14,494 (232)
Renal function in Japanese HIV-1-positive patients who switch to tenofovir alafenamide fumarate after long-term tenofovir disoproxil fumarate: a single-center observational study
AIDS Research and Therapy, 2021 Background Tenofovir disoproxil fumarate (TDF) has a strong antiviral effect, but TDF is known to cause renal dysfunction. Therefore, we are investigating preventing renal dysfunction by replacing TDF with tenofovir alafenamide fumarate (TAF), which is ...Kensuke Abe, Taku Obara, Satomi Kamio, Asahi Kondo, Junji Imamura, Tatsuya Goto, Toshihiro Ito, Hiroshi Sato, Nobuyuki Takahashi +8 moredoaj +1 more sourceWeek 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1 [PDF]
, 2019 Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917).
Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic ...Ajana, F, Arribas, JR, Bailey, J, Benson, P, Berenguer, J, Bhatti, L, Blaxhult, A, Brar, I, Bredeek, UF, Brinson, C, Brown, Kimberley, Brunetta, J, Casado, J, Clarke, A, Conway, B, Cotte, L, Crofoot, G, Cunningham, D, Cunningham, Douglas, de Vente, J, De Wit, S, De Wit, Stéphane, DeJesus, E, Dietz, C, Dretler, R, Eron, J, Eron, Joseph J, Fehr, J, Felizarta, F, Fichtenbaum, C, Flamholc, L, Florence, E, Galindo, MJ, Gallant, J, Gasiorowski, J, Gatell, JM, Gathe, J, Gazzard, BG, Girardy, P-M, Gisslèn, M, Gutierrez, F, Gutierrez, MDM, Hagins, D, Halota, W, Henn, S, Henry, WK, Horban, A, Hufkens, Veerle, Huhn, G, Iribarren, JA, Jain, M, Jezorwski, John, Johnson, MA, Katlama, C, Klein, M, Knobel, H, Lathouwers, Erkki, Lucasti, C, Martorell, C, McDonald, C, Mills, A, Molina, J-M, Morales-Ramirez, J, Mounzer, K, Moutschen, M, Murphy, D, Nahass, R, Negredo, E, Olivet, H, Opsomer, Magda, Orkin, C, Orkin, Chloe, Osiyemi, O, Perez-Valero, I, Petrovic, Romana, Piekarska, A, Pineda, JA, Podzamczer, D, Poizot-Martin, I, Portilla Sogorb, J, Post, F, Post, Frank A, Prelutsky, D, Pulido, F, Pulido, Federico, Rachlis, A, Raffi, F, Ramgopal, M, Rashbaum, B, Rauch, A, Rey, D, Reynes, J, Ricart, C, Richmond, G, Rivero, A, Ruane, P, Santos Gil, I, Scarsella, A, Scribner, A, Shafran, S, Shalit, P, Shamblaw, D, Slim, J, Stoeckle, M, Tashima, K, Teicher, E, Thalme, A, Ustianowski, A, Van Landuyt, Erika, Van Wijngaerden, E, Vandekerckhove, Linos, Vandercam, B, Voskuhl, G, Walmsley, S, Ward, D, Waters, L, Wilkin, A, Witor, A, Yazdanpanah, Y +118 morecore +2 more sourcesAn expert consensus for the management of chronic hepatitis B in Asian Americans. [PDF]
, 2018 BACKGROUND: Hepatitis B virus (HBV) infection is common with major clinical consequences. In Asian Americans, the HBsAg carrier rate ranges from 2% to 16% which approximates the rates from their countries of origin.Abbas, Abbas, Ahn, Beasley, Beasley, Bisceglie, Bogr, Brown, Buti, Centers for Disease Control, Chae, Chan, Chang, Chang, Chang, Chang, Chang, Chao, Chaung, Chen, Chen, Chen, Chen, Chi, Chien, Choe, Chu, Clemente, Della Corte, European Association for the Study of the Liver, Evans, Fang, Fattovich, Fontana, Fung, Gish, Hadziyannis, Halperin, Hann, Heathcote, Hongthanakorn, Hoofnagle, Hu, Huang, Hung, Hyun, Iino, Iloeje, Jeng, Keeffe, Kim, Komatsu, Konstantinou, Kowdley, Kuo, Kwong, Lai, Lai, Lai, Lai, Lampertico, Lau, Lau, Lee, Lee, Liang, Liaw, Liaw, Liaw, Liew, Lin, Lin, Lin, Liu, Liu, Liu, Lok, Lok, Lok, Loomba, MacLachlan, Manegold, Marcellin, Marcellin, Marcellin, Marcellin, Marcellin, Marcellin, Martin, Martin-Carbonero, Mast, McClune, McMahon, Mitchell, Monte, Murata, Mutimer, Nafa, Nguyen, Nguyen, Nikolopoulos, Pan, Pan, Pan, Pan, Pan, Pan, Pan, Pan, Pan, Pan, Papatheodoridis, Park, Park, Park, Patterson, Perrillo, Perrillo, Pollack, Prati, Qiu, Reijnders, Sarin, Seto, Seto, Sherman, Shim, Shiraki, Sinatra, Sinn, Soriano, Stevens, Takano, Takayama, Takkenberg, Terrault, Thibault, Thio, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tse, Wang, Wedemeyer, Wei, Wen, Wiseman, Wursthorn, Xie, Xu, Yi, Yi, Yu, Yu, Yuen, Yuen, Yuen, Yuen, Yuen, Zhang, Zhang, Zhang, Zou +173 morecore +2 more sourcesAtherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate [PDF]
Open Forum Infectious Diseases, 2019 Abstract Background In human immunodeficiency virus (HIV) treatment, tenofovir alafenamide (TAF) is associated with greater increases in all fasting cholesterol subgroups compared with tenofovir disoproxil fumarate (TDF).Huhn, Gregory D, Shamblaw, David J, Baril, Jean-Guy, Hsue, Priscilla Y, Mills, Brittany L, Nguyen-Cleary, Thai, McCallister, Scott, Das, Moupali +7 moreopenaire +2 more sourcesAssociation of Tenofovir Use With Risk of Incident Heart Failure in HIV-Infected Patients. [PDF]
, 2017 BackgroundThe antiretroviral medication, tenofovir disoproxil fumarate (TDF), is used by most human immunodeficiency virus-infected persons in the United States despite higher risks of chronic kidney disease.Chen, Ruijun, Estrella, Michelle M, Grunfeld, Carl, Horberg, Michael A, Hsue, Priscilla Y, Jotwani, Vasantha, Scherzer, Rebecca, Shlipak, Michael G +7 morecore +1 more sourceWeek 48 resistance analyses of the once-daily, single-tablet regimen darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials [PDF]
, 2019 Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is being investigated in two Phase III trials, AMBER (NCT02431247; treatment-naive adults) and EMERALD (NCT02269917; treatment-experienced, virologically suppressed ...Ajana, F, Antela, A, Antinori, A, Arasteh, K, Arribas, JR, Baugh, Bryan, Belonosova, E, Benson, P, Berenguer, J, Bhatti, L, Bickel, M, Bogner, J, Bredeek, F, Brown, Kimberley, Brunetta, J, Casado, J, Castelli, F, Chernova, O, Chirianni, A, Clarke, A, Conway, B, Cotte, L, Crofoot, G, Cunningham, D, De Los Santos, I, De Luca, A, De Meyer, Sandra, De Wit, S, DeJesus, E, deVente, J, Di Biagio, A, Dushkina, N, Eron, J, Esser, S, Estrada, V, Faetkenheuer, G, Felizarta, F, Florence, E, Franco, R, Galindo, MJ, Gallant, J, Galli, M, Garcia Del Toro, M, Garlicki, A, Gasiorowski, J, Gatell, JM, Gazzard, BG, Ghys, Anne, Girard, P-M, Gorgolas, M, Gutierrez, F, Gutierrez, MDM, Hagins, D, Halota, W, Henry, K, Horban, A, Jayaweera, D, Jessen, H, Jezorwski, John, Johnson, MA, Katlama, C, Kern, W, Klein, M, Kulagin, V, Lathouwers, Erkki, Lazzarin, A, Lucasti, C, Maggiolo, F, Martorell, C, Maserati, R, McDonald, C, McGowan, J, Mills, A, Mohsine, El Ghazi, Molina, J-M, Morales-Ramirez, J, Moutschen, M, Murphy, D, Mussini, C, Negredo, E, Opsomer, Magda, Orkin, C, Parczewski, M, Piekarska, A, Pineda, JA, Podzamczer, D, Poizot-Martin, I, Portilla Sogorb, J, Prelutsky, D, Rachlis, A, Raffi, F, Ramgopal, M, Rashbaum, B, Reeves, I, Rey, D, Reynes, J, Rivero, A, Rockstroh, J, Ruane, P, Rubio, R, Ryamova, E, Shafran, S, Shuldyakov, A, Sizova, N, Slim, J, Spinner, C, Stellbrink, H-J, Stoehr, A, Teicher, E, Tsybakova, O, Van Landuyt, Erika, Van Wijngaerden, E, Vandekerckhove, L, Vandercam, B, Vekerckhove, L, Vercam, B, Viciana, P, Voronin, E, Walmsley, S, Waters, L, Wilkin, A, Wong, Eric Y, Yakovlev, A, Yazdanpanah, Y +123 morecore +3 more sourcesEffectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort [PDF]
, 2019 Introduction: Concerns about dolutegravir (DTG) tolerability in the real-life setting have recently arisen. We aimed to estimate the risk of treatment discontinuation and virological failure of DTG-based regimens from a large cohort of HIV-infected ...Abeli C., Acinapura R., alungo A., Andreoni M., Angarano G., Antinori A., aracino A., atini A., azzarin A., Bagella P., Bai F., Baldelli F., Baldin G., Balotta C., Bandera A., Barocci V., Bassetti M., Blanc P., Bobbio N., Bonfanti P., Bonora S., Borderi M., Borgia G., Cacopardo B., Calcagno A., Capetti A., Capobianchi M. R., Capozzi M., Caramello P., Carletti F., Carrara S., Cascio A., Cassola G., Castagna A., Castelli F., Castelnuovo F., Cattelan A. M., Cauda R., Ceccherini-Silberstein F., Ceccherini-Silberstein F., Cecchetto M., Celesia B., Chiodera A., Cicalini S., Cingolani A., Cinque P., Colomba C., Costantini A., Cozzi-Lepri A., Cozzi-Lepri A., Cristaudo A., d'Arminio Monforte A., De Luca A., Di Biagio A., Di Caro A., Di Giuli C., Di Martino F., Di Perri G., Esposito V., Fabrizio C., Falasca K., Fanti I., Fontana Del Vecchio R., Francisci D., Galli L., Galli M., Gentile I., Giacometti I. A., Gianotti N., Girardi E., Gori A., Graziano S., Guaraldi G., i V., Iaiani G., Iardino R., Ippolito G., Lapadula G., lessandrini A., Lichtner M., Lo Caputo S., Lorenzini P., Lorenzotti S., Macchia M., Maddaloni L., Madeddu G., Maggiolo F., Maggiolo F., Magnani G., Manfrin V., Marchetti G., Marinello S., Mastrorosa I., Mazzarello G., Menzaghi B., Migliorino C., Milini P., Minardi C., Moioli M. C., Molteni C., Mondi A., Monno L., Mussini C., Nozza S., Nunnari G., ondero A., Orofino G. C., Pan A., Parruti G., Pellicano G., Pellizzer G., Perno C. F., Petrone F., Piolini R., Plazzi M. M., Pozzetto I., Prota G., Puoti M., Puzzolante C., Quartu S., Quiros Roldan E., Rezza G., Ridolfo A. L., Rivano Capparucia M., Rizzardini G., Rodano' A., Rossetti B., Rossotti R., Rusconi S., Rusconi S., Salpietro S., Sangiovanni V., Santoro M. M., Sarmati L., Savinelli S., Schiaroli E., Sciandra M., Segala D., Sighinolfi L., Sozio F., Starnini G., Suardi C., Tavelli A., Tavelli A., Tincati C., Truffa S., Ursitti M. A., Vecchiet J., Vergori A., Verucchi G., Viale P., Vichi F., Viscoli C., Viviani F., von Schloesser F., Vullo V. +155 morecore +4 more sourcesSwitching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study [PDF]
, 2016 BACKGROUND: Tenofovir alafenamide (TAF) is a novel tenofovir prodrug with improved renal and bone safety compared with TDF-containing regimens. We report the 48 week safety and efficacy of a once-daily single tablet regimen of elvitegravir 150 mg (E ...Abram, Michael E., Arribas, Jose R., Avihingsanon, Anchalee, Benson, Paul, Bloch, Mark, Cheng, Andrew, Chetchotisakd, Ploenchan, Crofoot, Gordon, Custodio, Joseph M., Fordyce, Marshall W., Gathe, Joseph, Gupta, Samir K., Lichtenstein, Kenneth, McCallister, Scott, Post, Frank A., Pozniak, Anton, Ramgopal, Moti, SenGupta, Devi, Wei, Xuelian +18 morecore +1 more source
